Sign up today to learn more about Synthego stock
EquityZen is a marketplace for shares of proven pre IPO tech companies
Synthego Stock
Genome Engineering Solutions
About Synthego Stock
Synthego is a provider of genome engineering solutions.The company's flagship product, CRISPRevolution, is a portfolio of synthetic RNA designed for CRISPR genome editing and research. CRISPR genome engineering technology enables scientists to easily and precisely edit the DNA of any genome. Select applications of gene editing include: pathway analysis, stem cells, and diagnostics. The company also offers two products: CRISPR-edited iPS cells and Engineered Cells. See here for more detailed information on Synthego's products.
Synthego aims to bring precision and automation to genome engineering, enabling rapid and costeffective research with consistent results for every scientist.
The company is headquartered in Silicon Valley, California and was founded in July 2012.
Investors
8VC
Guardant Health, Blend, AnchorFree, Sila Nanotechnologies, Illumio, Synthego, Asana, Addepar, Hims, Blink Health
Alexandria Venture
Arab Angel Fund
Founders Fund
Lyft, SpaceX, Spotify, Airbnb, Palantir Technologies, Stripe, Wish, Compass, Just, Flexport
Intel Capital
DocuSign, Joby Aviation, MongoDB, Synthego, Sprinklr, Kabam, Mirantis, Venafi, Joyent, Impinj
Menlo Ventures
Uber, Chime, Machine Zone, Tintri, Roku, Minted, Betterment, Rover, Synthego, Recursion Pharmaceuticals
ZhenFund
Funding History
| June 2013 | $8.3M |
|---|---|
| December 2016 | $41.9M |
| December 2016 | $4.4M |
| October 2018 | $116M |
| June 2020 | $100M |
Management
Chief Executive Officer
Paul Dabrowski
Press
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Synthego or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
